A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : UHDRS / Unified Huntington's Disease Rating Scale

[Related PubMed/MEDLINE]
Total Number of Papers: 139
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   UHDRS  (>> Co-occurring Abbreviation)
Long Form:   Unified Huntington's Disease Rating Scale
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Clinical manifestations of homozygote allele carriers in Huntington disease. HD
2019 Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes. HD, HDL2
2019 Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington's Disease. CAG, fMRI, HD
2019 Dysphagia characteristics in Huntington's disease patients: insights from the Fiberoptic Endoscopic Evaluation of Swallowing and the Swallowing Disturbances Questionnaire. BSE, FEES, HD, MoCA, SDQ, SWAL-QOL
2019 Identification of symbol digit modality test score extremes in Huntington's disease. HD, SDMT
2019 Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease. CDS, UHDRS-FAP
2018 Assessment Scales for Patients with Advanced Huntington's Disease: Comparison of the UHDRS and UHDRS-FAP. CDS, TFC, UHDRS-FAP
2018 Cannabinoids for Treatment of Dystonia in Huntington's Disease. HD, SD
2018 Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes. HD, JPRAT, TFC
10  2018 Evidence of cardiac electrical remodeling in patients with Huntington disease. CAG, HD
11  2018 Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy. 31 P MRS, BMI, GABA, HD, semi-LASER
12  2018 Extrastriatal degeneration correlates with deficits in the motor domain subscales of the UHDRS. HD, PCA, VBM
13  2018 Marriage as Protector for Nursing Home Admission in Huntington's Disease. UHDRS-FAP
14  2018 Pallidal Deep Brain Stimulation in Patients With Chorea-Acanthocytosis. ChAc, GPi
15  2018 Premanifest Huntington's disease: Examination of oculomotor abnormalities in clinical practice. ---
16  2018 Prospective evaluation of Globus pallidus internus deep brain stimulation in Huntington's disease. DBS, GPi, HD
17  2017 A liminal stage after predictive testing for Huntington disease. HD
18  2017 Comparison of Huntington's Disease in Europe and North America. HD
19  2017 Deficits in temporal processing correlate with clinical progression in Huntington's disease. HD, PI
20  2017 Down-regulation of miR-9* in the peripheral leukocytes of Huntington's disease patients. HD, HTT, miRNA
21  2017 Female Sexual Dysfunction in Presymptomatic Mutation Carriers and Patients with Huntington's Disease. FSFI, HD, TFC
22  2017 Health-related quality of life and unmet healthcare needs in Huntington's disease. HD, HRQoL, NPCS
23  2017 Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. SNP
24  2017 Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. HD
25  2017 Quantitative Gait Analysis in Patients with Huntington's Disease. HD
26  2017 Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease. AEs, HD
27  2017 Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease? CSF, HD, NFL, TFC, TMS
28  2016 Assistive Technology for Cognition andHealth-related Quality of Life inHuntington's Disease. ATC, HRQoL, TFC
29  2016 Clinical and genetic investigation of a Brazilian family with Huntington's disease. HD, MMSE
30  2016 Clinical manifestations of intermediate allele carriers in Huntington disease. HD, HTT, IAs, SF-36, TFC
31  2016 Reaction time and rhythm of movement in Huntington's disease. HD, RT, SPTP, TFC
32  2016 Wearable Sensors in Huntington Disease: A Pilot Study. ---
33  2015 Association of status redox with demographic, clinical and imaging parameters in patients with Huntington's disease. AOPPs, CAT, GPx, GR, HD, HTT, MDA, SOD
34  2015 Body composition analysis as an indirect marker of skeletal muscle mass in Huntington's disease. FFM, HD, TFC
35  2015 Cholinesterase inhibitors for rarer dementias associated with neurological conditions. AChE, CADASIL, CVLT-II, FTD, HD, MS, PSP, SDMT
36  2015 Dysphagia in Huntington's Disease: Correlation with Clinical Features. BSAS, DOSS, HD, TFC
37  2015 Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. CGI, EPA, HD, TMS-4
38  2015 Examining Huntington's disease patient and informant concordance on frontally mediated behaviors. FrSBe, HD
39  2015 High Protein Diet and Huntington's Disease. HD, HTT, mHTT
40  2015 How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease. MIG-HD, RIL-HD
41  2015 Informativeness of Early Huntington Disease Signs about Gene Status. BMI, HD
42  2015 Male sexual function in presymptomatic gene carriers and patients with Huntington's disease. HD, TFC
43  2015 Modelling the natural history of Huntington's disease progression. HD
44  2015 Substantia nigra hyperechogenicity in hypokinetic Huntington's disease patients. CN, LN, HD, IPD, SN, TCS
45  2015 Voxel-based analysis in neuroferritinopathy expands the phenotype and determines radiological correlates of disease severity. FTL, UDRS, VBM, VBR
46  2014 A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington's disease. HD, TFC
47  2014 Cognitive and autonomic dysfunction in presymptomatic and early Huntington's disease. EHD, PHD
48  2014 Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort. ---
49  2014 Huntington's Disease: Characteristics of Fallers. RMI
50  2014 Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease. HD, TBZ, TMT
51  2014 Optimising mobility outcome measures in Huntington's disease. BBS, HD, PPT, TMT, TUG
52  2014 Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature. AIMS, DBS, GPi, QOL, STN
53  2014 The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. BOP, BPnds, HD, HVs, PET
54  2013 A systematic review and meta-analysis of clinical variables used in Huntington disease research. HD
55  2013 Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. HD, IA, PHAROS
56  2013 Insulin sensitivity and early-phase insulin secretion in normoglycemic Huntington's disease patients. HD, HOMA-IR, TFC
57  2013 Refining the diagnosis of Huntington disease: the PREDICT-HD study. DCL, HD, MD, MD, UD
58  2013 Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. HD, MeDi, PHAROS
59  2013 Suicidal ideation in a European Huntington's disease population. CI, HD, HR, OR
60  2013 The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study. HD, UHDRS-FAP
61  2013 Unawareness of motor phenoconversion in Huntington disease. HD
62  2013 Unified Huntington's disease rating scale for advanced patients: validation and follow-up study. HD, TFC, UHDRS-FAP
63  2012 Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study. BBT, DGI, HD
64  2012 Clinical predictors of driving status in Huntington's disease. HD
65  2012 Clinical severity of Huntington's disease does not always correlate with neuropathologic stage. HD, MMSE
66  2012 Determinants of fitness to drive in Huntington disease. FTDr, HD
67  2012 Effect of tetrabenazine on motor function in patients with huntington disease. HD, JTHFT, MoCA, TBZ
68  2012 Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. HD
69  2012 Globus pallidus interna deep brain stimulation improves chorea and functional status in a patient with chorea-acanthocytosis. ChAc, GPi-DBS
70  2012 Huntington's disease from the patient, caregiver and physician's perspectives: three sides of the same coin? HD, QOL
71  2012 Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT. CAG, COHORT, HD, HTT
72  2012 Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. HD
73  2011 "Theory of mind" is impaired in Huntington's disease. HD, ToM
74  2011 A sensitivity comparison of clinical tests for postural instability in patients with Huntington's disease. HD, ICCs, MMSE, PI
75  2011 An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. HD
76  2011 Exploring the correlates of intermediate CAG repeats in Huntington disease. HD, PHAROS
77  2011 Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease. apoA-IV, BBB, CSF, ELISA, HD, QAlb
78  2011 Seven-year clinical follow-up of premanifest carriers of Huntington's disease. HD, ROC, SDMT, TMT, WMS
79  2011 The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene. MMSE, TFC
80  2011 What is the impact of education on Huntington's disease? CAG, HD
81  2010 A randomized, placebo-controlled trial of latrepirdine in Huntington disease. ADAS-cog, HD, MMSE
82  2010 Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease. HD, NMRS
83  2010 Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement? HD
84  2010 Earliest functional declines in Huntington disease. FAS, HD, TFC
85  2010 Factors predicting discharge of Huntington's disease patients from a neuropsychiatry unit. ---
86  2010 Fall risk assessment using the Tinetti mobility test in individuals with Huntington's disease. HD, TMT
87  2010 Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. mI, MRS, NAA, preHD, tNAA
88  2010 QEEG Measures in Huntington's Disease: A Pilot Study. AP, HD, MRI, qEEG, TFC
89  2009 A pilot study using nabilone for symptomatic treatment in Huntington's disease. HD, NPI
90  2009 Clinical assessment of mobility and balance impairments in pre-symptomatic Huntington's disease. FRT, pre-HD, TUG
91  2009 Clinical measurement of mobility and balance impairments in Huntington's disease: validity and responsiveness. BBS, HD, TUG
92  2009 Health-related quality of life in Huntington's disease: Which factors matter most? HD, HRQoL
93  2009 Mobility and falls in people with Huntington's disease. BBS, FAS, HD, IS, TFC, TUG
94  2009 Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. AP, DA, HD, TBZ
95  2008 Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. HD
96  2008 Behavioural problems in Huntington's disease using the Problem Behaviours Assessment. HD, PBA
97  2008 Falls and gait disturbances in Huntington's disease. ---
98  2008 Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. HD, VBM
99  2008 The relationship between CAG repeat length and clinical progression in Huntington's disease. CAGn, HD
100  2008 Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease. HD, ICC